Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1673
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2497
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    51,131.00
    -582.23 (-1.13%)
     
  • CMC Crypto 200

    1,334.43
    -62.10 (-4.45%)
     
  • S&P 500

    5,109.02
    +60.60 (+1.20%)
     
  • DOW

    38,290.53
    +204.73 (+0.54%)
     
  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     
  • GOLD FUTURES

    2,351.30
    +8.80 (+0.38%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

This Growth Stock Is Down 38% and Wall Street Says It's Worth Buying Hand Over Fist

This Growth Stock Is Down 38% and Wall Street Says It's Worth Buying Hand Over Fist

With the stock falling 37.8% over the last 12 months, shareholders of Bionano Genomics (NASDAQ: BNGO) are bound to be getting a bit frustrated. The genome mapping device manufacturer's fortunes haven't done anything but improve in recent memory, but the market's reception to its successes continues to be fairly cool.